Edwards Lifesciences Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Bernard Zovighian
Chief executive officer
US$12.9m
Total compensation
| CEO salary percentage | 7.6% |
| CEO tenure | less than a year |
| CEO ownership | 0.003% |
| Management average tenure | 5yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29
Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jul 16Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Jun 30Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Jun 15Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed
Jun 12Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
May 31Edwards Lifesciences (NYSE:EW) Has A Rock Solid Balance Sheet
Apr 03What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing?
Mar 22Investors Shouldn't Overlook The Favourable Returns On Capital At Edwards Lifesciences (NYSE:EW)
Mar 10Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Feb 26Edwards Lifesciences downgraded to market perform at Raymond James on growth challenges
Feb 06Edwards Lifesciences slips as Piper downgrades on challenging setup
Jan 30Edwards Lifesciences: Short-Term Growth Worries Have Created An Opportunity
Jan 18Edwards Lifesciences: Catalysts For 2023 And Beyond
Dec 30Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 28Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Dec 16Edwards Lifesciences CEO Michael Mussallem to retire
Dec 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$13m | US$973k | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$1b |
| Mar 31 2023 | n/a | n/a | US$1b |
| Dec 31 2022 | US$3m | US$642k | US$2b |
Compensation vs Market: Bernard's total compensation ($USD12.87M) is about average for companies of similar size in the US market ($USD13.62M).
Compensation vs Earnings: Bernard's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Bernard Zovighian (55 yo)
less than a year
Tenure
US$12,869,020
Compensation
Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$12.87m | 0.0030% $ 1.5m | |
| Corporate VP & CFO | 10.3yrs | US$5.95m | 0.045% $ 23.1m | |
| Corporate Vice President of Strategy & Corporate Development | 8.3yrs | US$4.29m | 0.034% $ 17.4m | |
| Corporate VP and Group President of TAVR & Surgical Structural Heart | 1.3yrs | US$5.40m | 0.034% $ 17.2m | |
| Corporate VP of Advanced Technology & Chief Scientific Officer | 5.3yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Corporate VP & General Counsel | 4.7yrs | no data | no data | |
| Corporate Vice President of Public Affairs | 10.9yrs | no data | no data | |
| Corporate Vice President of Human Resources | 11.8yrs | no data | no data | |
| Senior Vice President of Quality & Regulatory Compliance | less than a year | no data | no data | |
| GM & Senior VP of Surgical Structural Heart | less than a year | no data | no data | |
| VP & Corporate Controller | no data | no data | 0.0050% $ 2.6m |
5.0yrs
Average Tenure
57.5yo
Average Age
Experienced Management: EW's management team is considered experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$12.87m | 0.0030% $ 1.5m | |
| Independent Director | 9.3yrs | US$335.06k | 0.011% $ 5.8m | |
| Independent Director | 3.8yrs | US$329.97k | 0.00082% $ 420.5k | |
| Non-Executive Chairman of the Board | 24.3yrs | US$2.87m | 0.67% $ 344.0m | |
| Independent Director | 8.2yrs | US$335.06k | 0.011% $ 5.8m | |
| Independent Director | 7.8yrs | US$356.42k | 0.0040% $ 2.1m | |
| Independent Director | 9.5yrs | US$347.97k | 0.011% $ 5.6m | |
| Lead Independent Director | 8.6yrs | US$364.97k | 0.0048% $ 2.5m | |
| Independent Director | 4yrs | US$334.97k | 0.0014% $ 697.3k |
8.2yrs
Average Tenure
65yo
Average Age
Experienced Board: EW's board of directors are considered experienced (8.2 years average tenure).